Search Results - "Zemmour, C"

Real-world implementation of a geriatric-specific ERAS protocol in patients undergoing colonic cancer surgery by Meillat, H., Braticevic, C., Zemmour, C., Brun, C., Cécile, M., Faucher, M., de Chaisemartin, C., Lelong, B.

“…The aim of this single-center observational study was to evaluate the impact of implementing Enhanced Recovery After Surgery (ERAS) protocols, combined with…”
Get full text

Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study by de Nonneville, A., Gonçalves, A., Zemmour, C., Cohen, M., Classe, J.M., Reyal, F., Colombo, P.E., Jouve, E., Giard, S., Barranger, E., Sabatier, R., Bertucci, F., Boher, J.M., Houvenaeghel, G.

“…Triple-negative breast cancers (TNBCs) are considered as associated with poor outcome, but prognosis of subcentimetric, node-negative disease remains…”
Get full text

Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome by Bouchacourt, B., Hospital, M. A., Zemmour, C., Rey, J., d’Incan, E., Charbonnier, A., Mohty, B., Saillard, C., Bonnet, S., Collignon, A., Gelsi-Boyer, V., Mozziconacci, M. J., Blaise, D., Vey, N.

“…Although complete remission (CR) is achieved in 50 to 70% of older fit patients with acute myeloid leukemia (AML), consolidation therapy in this age group…”
Get full text

Circulating tumour DNA as an early marker of recurrence and treatment efficacy in ovarian carcinoma, the CIDOC study by Sabatier, R., Pomel, C., Colombo, P.-E., Narducci, F., Garnier, S., Carbuccia, N., Guille, A., Birnbaum, D., Zemmour, C., Lambaudie, E.

Get full text

A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study by Collignon, A., Hospital, M. A., Montersino, C., Courtier, F., Charbonnier, A., Saillard, C., D’Incan, E., Mohty, B., Guille, A., Adelaïde, J., Carbuccia, N., Garnier, S., Mozziconacci, M. J., Zemmour, C., Pakradouni, J., Restouin, A., Castellano, R., Chaffanet, M., Birnbaum, D., Collette, Y., Vey, N.

“…Targeted next-generation sequencing (tNGS) and ex vivo drug sensitivity/resistance profiling (DSRP) have laid foundations defining the functional genomic…”
Get full text

Motor-evoked potential gain is a helpful test for the detection of corticospinal tract dysfunction in amyotrophic lateral sclerosis by Duclos, Y, Grapperon, A.M, Jouve, E, Truillet, R, Zemmour, C, Verschueren, A, Pouget, J, Attarian, S

“…Highlights • Motor-evoked potential (MEP) gain is decreased in patients with amyotrophic lateral sclerosis (ALS). • MEP gain may allow the early detection of…”
Get full text

Early prognostic factors in septic shock cancer patients: a prospective study with a proteomic approach by Mokart, D., Saillard, C., Zemmour, C., Bisbal, M., Sannini, A., Chow‐Chine, L., Brun, J.‐P., Faucher, M., Boher, J.‐M., Toiron, Y., Chabannon, C., Borg, J.‐P., Gonçalves, A., Camoin, L.

“…Background Organ failures are the main prognostic factors in septic shock. The aim was to assess classical clinico‐biological parameters evaluating organ…”
Get full text

A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB (R²) COMBINATION IN PATIENTS WITH HIGH‐RISK REFRACTORY/RELAPSED DIFFUSE LARGE B‐CELL LYMPHOMA by Bouabdallah, R., Zemmour, C., Schiano de Collela, J., Slama, B., Bladé, J., Belmecheri, N., Coso, D., Montes de Oca, C., Stoppa, A., Aurran‐Schleinitz, T., Cournier, S., Ivanov, V., Mescam, L., Blaise, D.

Get full text

Variability induced by the MR imager in dynamic contrast-enhanced imaging of the prostate by Brunelle, S., Zemmour, C., Bratan, F., Mège-Lechevallier, F., Ruffion, A., Colombel, M., Crouzet, S., Sarran, A., Rouvière, O.

“…To evaluate the variability induced by the imager in discriminating high-grade (Gleason≥7) prostate cancers (HGC) using dynamic contrast-enhanced MRI. We…”
Get full text

1403 SIGNIFICANT IMPROVEMENT OF COMPLETE EVR IN HCVAC PHASE II CLINICAL TRIAL WHEN ADDING TG4040 THERAPEUTIC VACCINE TO PEGIFNα2A AND RIBAVIRIN by Wedemeyer, H, Janczewska, E, Wlodzimierz, M, Stanciu, C, Habersetzer, F, Carreno, V, Di Bisceglie, A.M, Tanasescu, C, Flisiak, R, Romero-Gomez, M, Fich, A, Zemmour, C, Fournillier, A, Zerr, P, Agathon, D, He, H, Bonnefoy, J.-Y, Inchauspe, F, Limacher, J.-M

Get full text

Neutrophil-to-Lymphocyte Ratio on Post-operative Day 3: A Simple Tool to Exclude Clinically Relevant Postoperative Pancreatic Fistula after Pancreatoduodenectomy by Garnier, J., Alfano, M.-S., Robin, F., Ewald, J., Al-Faraï, A., Palen, A., Sebai, A., Mokart, D., Delpero, J.-R., Sulpice, L., Zemmour, C., Turrini, O.

Get full text

8TiPCirculating tumour DNA as an early marker of recurrence and treatment efficacy in ovarian carcinoma, the CIDOC study by Sabatier, R, Pomel, C, Colombo, P-E, Narducci, F, Garnier, S, Carbuccia, N, Guille, A, Birnbaum, D, Zemmour, C, Lambaudie, E

Get full text

Adjuvant chemotherapy in pT1ab node-negative triple negative breast carcinomas: Results of a national multi-institutional retrospective study by De Nonneville, A., Gonçalves, A., Zemmour, C., Cohen, M., Classe, J.M., Reyal, F., Colombo, P.E., Jouve, E., Giard, S., Barranger, E., Sabatier, R., Bertucci, F., Boher, J.M., Houvenaeghel, G.

Get full text

Determinants of favorable or unfavorable opinion about euthanasia in a sample of French cancer patients receiving palliative care by de Nonneville, Alexandre, Chabal, Théo, Marin, Anthony, La Piana, Jean Marc, Fichaux, Marie, Tuzzolino, Véronique, Duffaud, Florence, Auquier, Pascal, Boulanger, Augustin, Baumstark, Karine, Salas, Sébastien

“…Opinion about euthanasia has been explored among the general population and recently in patients receiving palliative care. 96% of the French population…”
Get full text

Determination of the free plasma fraction of drugs by Bruguerolle, B, Jadot, G, Valli, M, Bouyard, L, Zemmour, C, Mouchet, J, Bouyard, P

Get more information